Debio 1452, formerly called AFN-1252 (Fig. 1), is an investigational FabI inhibitor that has demonstrated potent activity against Staphylococcus aureus (1–5). Currently, Debio 1450 (prodrug of Debio 1452) is in clinical development by the Debiopharm Group (6, 7). Debio 1452 selectively inhibits bacterial enoyl-acyl carrier protein (enoyl-ACP) reductase, an essential step in the elongation cycle...

هدف: هدف از پژوهش حاضر مقایسۀ واکنش ­پذیری هیجانی و نظریه ذهن کودکان بر اساس سبک ­های ابرازگری مادرانشان بود. روش: روش توصیفی نوع علّی-مقایسه­ ای بود در دو گام به صورت آنلاین انجام رسید. ابتدا با استفاده نمونه ­گیری دسترس، تعداد 105 نفر مادرانی که نمرات آن­ها هر یک پرسشنامه کینگ امونز (1990)، دوسوگرایی (1990) کنترل راجر نشوور (1987) انحراف استاندارد بالاتر میانگین دست آمد (در گروه 35 نفر) دوم وا...

The antifungal susceptibilities of 40 clinical and environmental isolates of A. terreus sensu stricto to amphotericin B, terbinafine, itraconazole, and voriconazole were determined in accordance with CLSI document M38-A2. All isolates had itraconazole and voriconazole MICs lower than epidemiologic cutoff values, and 5% of the isolates had amphotericin B MICs higher than epidemiologic cutoff val...

To the best of our knowledge, Non-O1 Vibrio cholerae (NOVC) bacteremia has never been documented in Pakistan. This case report is the first reported case of bacteremia in an infant due to NOVC in Pakistan. A neonate was admitted to a hospital with fever and no history of diarrhea. The isolate was identified biochemically and serologically and was sensitive to all the drugs tested as per CLSI 20...